Intelligent Relations
Preston by Intelligent Relations
Jonathan Wosen
Gray shield icon
Is this you?
Claim your profile.

Jonathan Wosen

West Coast Biotech & Life Sciences Reporter

AS SEEN ON
STAT News

Preston's Summary

Jonathan Wosen is a West Coast biotech & life sciences reporter at STAT. He focuses on medicine and healthcare, with a keen interest in educational policy and school governance, drawing on his extensive academic background in immunology and science communication. Jonathan's work has been featured in notable publications including The San Diego Union-Tribune, Los Angeles Times, and The Boston Globe.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

San Diego, United States (Local)

Coverage Attributes:

Beta
Informative: 56 %
Data Driven: 38 %
Opinion: 3 %
Interviews Q&as: 1 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Educational Policy
  • School Governance

Pitching Insights

Jonathan Wosen's articles predominantly focus on the scientific and healthcare sectors, particularly biotech, medical research, drug development, pharmaceuticals, and genetic disorders. His coverage heavily involves citing data and government announcements.

When reaching out to Jonathan with pitches or expert commentary, consider providing insights backed by credible data or referencing recent relevant government announcements in the scientific and healthcare fields. Pitches that align with his focus on breakthroughs in biotech and drug development as well as advancements in medical research are likely to be well-received.

As his geographic focus is not specified but covers global topics within the industry of interest, it is important for sources to provide insights from a wide range of locations without being limited geographically.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Alice Park

Alice Park

Dept Head
********rk@******om
Publications
TIME, AOL, Inc., RealClearHealth, Magzter
Most recent topics
Not enough data
Rebecca Trager

Rebecca Trager

Senior Us Correspondent
******r@******g
Publications
Chemistry World
Most recent topics
Not enough data
Jason Mast

Jason Mast

Reporter
********st@**********om
Publications
STAT News, RamaOnHealthcare, The Boston Globe
Most recent topics
Not enough data
Huanjia Zhang

Huanjia Zhang

Science & Health Reporter
**********ang@**********com
Publications
GenomeWeb, 360Dx
Most recent topics
Not enough data
Adam Feuerstein

Adam Feuerstein

Senior Writer, National Biotech Columnist
************ein@**********om
Publications
STAT News, RamaOnHealthcare
Most recent topics
Not enough data
Robin Fields

Robin Fields

Global Health Reporter
Publications
Undark Magazine
Most recent topics
Not enough data

Articles

STAT News

Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea

Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea

By: Jonathan Wosen

The new firm, Caspian Therapeutics, is launching with $50 million in financing to develop menin inhibitors for diabetes and other cardiometabolic diseases. The initial funding, led by BVF Partners and joined by Eli Lilly and members of Kura's leadership team, among others, is meant to advance Caspian's lead small molecule drug through an early-phase clinical trial in diabetes and support the development of a second candidate.

© 2026 Intelligent Relations